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SUMMARY
In the late 1970's the options for treatmentofoesophageal cancer were limited.
When cure was thoughtpossible, resection wasperformed by theIvorLewis or
oesophagogastrectomy techniques. Mortality was high, local recurrence rates
disappointing, and long-term survivalpoor. For thosepatients whose tumours
could not be resected, palliative intubation required open operation with high
morbidity, andgavepoorqualityoflife. In 1994,selectivescreeningisdiagnosing
cancers early, more extensive resections arepossible with lowermortality, and
fewer local recurrences. Adjuvant therapy is increasing the operability rates.
Gradually the facade ofpoor prognosis is being etched away, so that more
patients are being given betterquality oflife, and cure is a distinctpossibility.
Palliation can be achieved endoscopically by dilatation, intubation or laser
ablation combined with local external beam radiation. Mortality forpalliative
procedures is now considerably reduced.
INTRODUCTION
In 1987 a review ofthe treatment ofoesophageal cancer overthe preceding ten
years was undertaken at the Royal Victoria Hospital. Of the 401 patients
presenting to the hospital, exploratory surgery was performed on 247, and 221
underwent resection. Clear tumour margins were obtained in 112, 82 ofwhom
survived their surgery. Thus only 20 per cent of those who presented for
oesophageal surgery left hospital with their disease completely resected. The
five-year survival following resection was 13.2% (Fig. 1).
A broad range of factors affecting survival following resection have been
examined, and while many were found to be significant, the only independent
predictors of survival were sex, involvement of proximal resection margins,
curative resection and presence of nodal metastases
By way of palliation, 113 Celestin tubes were passed at open laparotomy or
thoracotomy and26Atkinsontubesintroducedendoscopically. In ninepatients
thetumourswere bypassed, 21 patientswere referredforprimaryradiotherapy,
and 14 were unfit for surgical intervention.
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Fig 1. Probability of survival following oesophageal resection, RVH 1977-1986. All patients.
Following a transition period in 1986-1987, a number of changes have been
made in the approach to oesophageal malignancies. Endoscopic surveillance
has been introduced for patients with premalignant pathology. Laser ablation
has become the treatment of choice for palliating inoperable tumours. For
those in whom cure is thought possible, the more extensive total thoracic
oesophagectomy operation has been introduced withthe aimofresecting more
of the proximal oesophagus, performing the anastomosis in the neck. Of the
139 oesophageal resections performed between 1988 and 1992, 73 have
involved total oesophagectomy; 20 have been for benign or premalignant
disease.
In this paper we describe the changes in our approach to oesophageal cancer,
the results of these changes, and outline future plans for treating this difficult
disease.
DIAGNOSIS AND SURVEILLANCE OF OESOPHAGEAL PREMALIGNANT
CONDITIONS
It has become apparent that peptic disorders are associated with oesophageal
cancer. In the 1977-86 series, 21.5% ofpatients had hiatal hernia, and a further
24.3% had other peptic disease. In particular, patients whose oesophagitis has
advanced to the stage where the oesophageal lining has changed to columnar
intestinal epithelium (Barrett's metaplasia), have a cancer risk 40 times that of
thenormalpopulation.' Inconjunctionwith ourcolleagues ingastro-enterology,
it is our practice to maintain endoscopic surveillance for all patients with
Barrett's metaplasia. When metaplastic columnar epithelium is found in the
© The Ulster Medical Society, 1994.
128Oesophageal cancer
true oesophagus above the oesophagogastric junction, yearly surveillance is
recommended. When dysplasia is reported, more frequent and more intense
surveillance is required. If any biopsy is reported as containing high grade
dysplasia, resection is recommended.
Thirty-three of 112 cancers in the latter series had metaplastic epithelium
present in the oesophagus adjacent to the tumour. Six ofthese had been under
surveillance, and the five Stage I tumours have a good chance of long-term
survival. In addition, 12 resections were performed for Barrett's metaplasia
without cancer.
More recently we have turned our attention to molecular biology in an attempt
to determine which patients are likely to develop tumours. Oncogenes, genetic
mutations associated with tumour development, have been identified in
oesophageal tumours from a tissue bank set up at the Royal Victoria Hospital
(A Ritchie). Mutations of the p53 tumour suppressor gene, which render it
inactive, have also been demonstrated in tumour tissue from this bank (K
Gleeson, Department ofMedical Genetics, The Queen's University ofBelfast).
It is hoped that assaying for these mutant genes or their protein products will
help indicate premalignant change in patients under surveillance. Oncogenes,
being unique to malignant and premalignant cells, would be suitable targets for
anti-tumour antibodies, and this treatment modality may be available to us in
the future.
RESECTIONS FOR OESOPHAGEAL CANCER
The standard oesophagogastrectomy procedure is usually performed via a left
thoraco-abdominal incision (Fig 2). The proximal limit of resection is judged
by the surgeon to be a point 5-7 cm proximal to the palpable tumour. The
anastomosis is made below the aortic arch within the chest. When the tumour
encroaches significantly onto the stomach the resection is extended to include
a total gastrectomy. The Ivor Lewis oesophagogastrectomy devised for more
proximal tumours, requires an uppermidline laparotomy formobilization ofthe
stomach and a right thoracotomy to resect the tumour, again with a 7 cm
margin, the anastomosis being above the level ofthe azygos vein. The decision
as to whether the oesophagogastrectomy or Ivor Lewis approach was used
depended on the barium and endoscopic findings.
Total thoracic oesophagectomy is performed using the technique described by
Matthews2 using a left thoraco-abdominal incision, resembling that for the
oesophago-gastrectomy but with further dissection of the oesophagus above
the aortic arch into the neck from below. The anastomosis is performed via a
small cervical incision. This operation is performed whenever there is enough
stomach available after adequate tumourresection to reach comfortably to the
neck. It is therefore not used for true gastric fundal tumours where an
oesophago-gastrectomyortotal gastrectomy isperformed. Thedecisiononthe
extent of resection does not need to be made until the tumour is mobilised and
is fully assessible.
Mention must be made ofthe 'transhiatal' oesophagectomy approach which is
performed via a laparotomy with blunt dissection of the oesophageal tumour
and anastomosis in the neck. This operation does fulfill the requirements of
total thoracic oesophageal resection with the reduced morbidity ofthe cervical
© The Ulster Medical Society, 1994.
129The Ulster Medical Journal
anastomosis but avoiding some of the complications of thoracotomy. While
recognising its place in the treatment of benign conditions such as advanced
achalasia and Barrett's metaplasia, we have reservations about its use in
malignant conditions.
* OESOPHAGOGASTRECTOMY * IVOR LEWIS
OESOPHAGECTOMY
* OESOPHAGO-TOTAL
GASTRECTOMY
* TOTAL THORACIC
OESOPHAGECTOMY
Fig 2. Operative approaches to oesophageal cancer.
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MORBIDITY/MORTALITY
The National Confidential Enquiry into Postoperative Deaths (NCEPOD)3 for
1992 recognised oesophagectomy as a procedure with risks "worse than that
oftransplantation and cardiac surgery". This is especially the case in the hands
of the occasional oesophageal surgeon.4 Our mortality for oesophagectomy
improved from 39% in 1977 to 11% in 1985. This improvement was maintained
with the introduction ofthe more extensive procedures. The mean mortality for
total thoracic oesophagectomy over the first five years was 10.9%, with only
one death in the last two years. The mortality for the oesophagogastrectomy
procedures was 13.5% in the same period. Much of the improvement over
recent years has been a result of better patient selection on the basis of our
earlier experience, and also from improvements in postoperative intensive
care. An important contribution has been the decrease in anastomotic leaks.
Intrathoracic anastomotic leak has a mortality ofover 50%. The incidence has
been lowered bythe use ofmechanical staplers.5Cervical anastomotic leakhas
occurred in two patients (4.3%), with no deaths. Leaks in the neck usually drain
via the local incision without mediastinal or pleural contamination. The
resulting fistulae drain well and close spontaneously. Non-fatal complications
occurred in 23%, being comparable for all procedures.
TABLE
Factors favourably affecting survival following resection for oesophageal
cancer 1977-1986 (univariate analysis)
Covariate p value
Female sex 0.003
Curative resection <0.001
Nodes free of metastases <0.001
Clear proximal margin <0.001
Tumour confined to oesophageal muscle 0.003
Ivor Lewis operation 0.004
Favourable differentiation 0.02
Clear distal margin 0.057
Short symptom duration 0.041
Squamous histology 0.07
Site of tumour (middle third/lower third/cardia) 0.14
Weight loss 0.16
Year of operation 0.57
Age 0.57
Surgeon grade 0.89
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SURVIVAL FOLLOWING RESECTION OF OESOPHAGEAL CANCER
Thefactors affecting survival afterresection and discharge from hospital forthe
1977-1986 series are summarised in Table I. A multivariate analysis showed
that onlyfemale sex, curative resection, absence ofnodal metastases and clear
proximal resection margins were independent predictors oflong-term survival.
Nodal metastases, the most significant predictor of survival, are indicative of
systemic dissemination of tumour. This is reflected by the fact that regardless
ofthetypeofoperation there issubstantial tumour-related mortality inthe early
months aftersurgery due to undetected metastatic disease. What is clearisthat
the future treatment of carcinoma of the oesophagus must include systemic
therapy. Many surgeons have now become interested in chemotherapy, in
conjunction with surgery. Until recentyears, no chemotherapeutic regimeshad
satisfactory effects on solid tumours, though 5-fluorouracil had some effect in
gastrointestinal tract adenocarcinoma.
Successintreating squamouscarcinoma ofthe larynxandlungwithcisplatinum
logically progressed to trials on oesophageal cancer. 6,7,8 The problems of
toxicity and patient compliance are now better controlled, and regimes of
rehydration, diuretics, sedation and anti-emetics are being standardised. Pilot
studies in Belfast have shown the feasibility of such therapy, and patients are
being entered in a number of trials of preoperative chemotherapy.
The other main cause of early death is tumour recurrence at the anastomosis.
Recurrence is related to the type of operation and particularly the presence of
tumour in the vicinity ofthe proximal resection margin. This is reflected in the
survival curves for these two factors (Figs. 3 and 4).
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Fig 3. Probability of survival following oesophageal resection, RVH 1977-1986. (p = 0.004)
Operation type. (Operative deaths excluded).
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Fig 4. Probability of survival following oesophageal resection, RVH 1977-1986. (p = 0.0006)
Proximal margin. (Operative deaths excluded).
With the introduction of total thoracic oesophagectomy the incidence of
proximal limit involvement and anastomotic recurrence has dropped to zero.
Despite attempts to gain a greater proximal margin in both Ivor Lewis and
oesophagogastrectomy resections, the recurrence rates remain high for these
operations (38.5%forIvorLewis, 15.8%foroesophagogastrectomy). Thedistal
clearance is similar between all groups though a number of tumours have
recurred on the lesser curve of the stomach. The short and medium term
survival in the total thoracic oesophagectomy group reflects the improvement
in proximal tumour clearance (Fig. 5).
PALLIATION OF UNRESECTABLE OESOPHAGEAL CANCER
Thirty eight per cent of oesophageal cancers present to this hospital in an
inoperable state. Palliation, therefore, is a major part of the treatment of
oesophageal cancer. Inabilitytoswallowones' ownsaliva issuch anunpleasant
end, that aggressive measures are usual'ly employed to restore at least a liquid
diet, despite the considerable risks of some of the procedures.
Resection is a major debilitating operation with high risk and prolonged
recovery. It is not indicated when metastatic disease is detected during
preoperative staging or open exploration, nor when resection is likely to be
incomplete and the prognosis poor. Tumour bypass is advocated by some
authorities, especially inthecaseoftracheo-oesophagealfistula.9 Theoperation
is as extensive a procedure as resection with an anastomosis in the chest. The
experience in our 1977-1986 series showed very poor results for bypass.
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Intubation ofthe tumour can maintain a lumen adequate to allow a pure6d diet.
An Atkinson tube may be placed at endoscopy, or a Celestin tube at open
operation. As the mortality for open insertion was 26% in the 1977-1986, this
method is now generally avoided. Mortality from endoscopic placement is low,
but the tubes are sometimes poorly tolerated and blockage is not an infrequent
complication. Expandible metal mesh stents are now available and claims of
lower complication rates have been made.10 We find that that these stents are
relatively easily placed under radiological control but their expense limits their
widespread use. They may be over-used in patients who should be offered a
chance of a curative resection.
Laser ablation overcomes some of the disadvantages of intubation in that
tumours high in the oesophagus can be treated, and a degree offlexibility and
motility is maintained in the oesophagus to the extent that a relatively normal
diet is tolerated by many patients. It is now the treatment ofchoice in palliating
tumours ofthetrueoesophagus. Itis less suitablefortumours ofthe oesophago-
gastric junction or for tumours which cannot be dilated to allow introduction of
the endoscope carrying the laser. For undilatable tumours one must resort to
traction intubation via laparotomy or, in dire circumstances, a jejunostomy.
At present, chemotherapy has no place in the routine palliation ofoesophageal
carcinoma. Currenttherapy is not aimed at palliation but rather at preoperative
tumour shrinkage as described above, or for patients with a high probability of
micrometastatic disease suggested by extra-oesophageal invasion, nodal
metastases or residual disease after resection.
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Fig. 5 Probability of survival following total thoracic oesophagectomy compared to
oesophagogastrectomy (Ivor Lewis and standard) 1988-1992.
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Fluid and nutritional balance can be maintained by insertion of a jejunostomy
and sometimes a narrow bore nasogastric feeding tube. Neither method
relieves the complete dysphagia but has the effect of prolonging life of the
patientwiththedistressing symptom of'drowning in hisown saliva'. The limited
uses of these techniques have been as a bridge to surgery, to allow a patient
time to arrange his affairs or for specific social reasons. Laparotomy and
jejunostomy has a high mortality rate in this setting.
Radiotherapy currently has a role in obtaining local control of tumour, both
squamous and adenocarcinoma, in patients who are unfit for surgery. It also
has a role in the pain control of metastatic lesions. Unfortunately, when used
as palliation for dysphagia in patients with advanced disease, it is less useful.
Our 1977-1986 review included a number of such patients referred for
dilatation after radiotherapy. The perforation rate was 44% and mortality
almost as high. The trend continues in our current practice. We would prefer to
palliate dysphagia with laser ablation and then use an endo-oesophageal stent
to maintain a lumen. When the disease is regarded as local, radiotherapy may
then be used with curative intent.
CONCLUSIONS
Changes made in the approach to oesophageal cancer in the late 1980's have
increasedthechancesofsurvival. Neoadjuvant chemotherapy andradiotherapy
are on trial in an attempt to improve operability and survival. The future
direction ofthe science ofoncology will clearly involve tumour manipulation at
the molecular biological level. The Royal Victoria Hospital in association with
The Queen's University of Belfast is at the forefront of research into the use of
these new technologies in relation to oesophageal cancer. Clinical benefits can
be expected in the not too distant future. The surgeon's role is changing from
being the sole hope for patients with oesophageal cancer to being one arm of
a multidisciplinary approach.
We thank Dr Chris Patterson for assistance with statistical analysis, andMiss May Wellerfortyping
the manuscript.
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